Alpha Cognition Inc. (ACOG) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Alpha Cognition Inc. (ACOG) closed at USD 8.65 on 2026-10-14, a change of +31.1 % over the past year, with a market capitalization of USD 184.02M.

Alpha Cognition Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Alpha Cognition Inc. key figures

Previous close

USD 8.65 (2026-10-14)

1-year change

+31.1 %

Market cap

USD 184.02M

Enterprise value

USD 142.64M

P/E ratio (trailing)

-6.71

P/E ratio (forward)

-13.63

EPS (trailing)

-1.26

EPS (forward)

-0.62

PEG ratio

n/a

Price to book

3.47

Revenue growth

267.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.88

Employees

71

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Alpha Cognition Inc.

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Alpha Cognition Inc. and compare it with other stocks.